What’s driving the Immutep share price in June?

a doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.a doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.

The Immutep Ltd (ASX: IMM) share price has gyrated in recent months, having slumped from a 52-week high of 71 cents back in November to close Friday’s session at 37 cents.

Investors pushed the stock to 52-week lows by April this year, when it then found buyers at the 30.5 cents mark, and it has been on an upward ascent since.

As seen below, the Immutep share price has gained around 7% in the past month, despite the period of volatility leading up to this point.

TradingView Chart

What tailwinds are there for the Immutep share price in June?

The Immutep share price came out of May in a healthy position, having strengthened throughout the month. Investors pushed the stock around 24% higher in May following two updates regarding the company’s lead drug candidate, efti.

Study readouts are key in the growth narrative of biotech stocks like Immutep. For the company, news around its etfi compound has been paramount for its share price appreciation.

Most recently, Immutep advised of another phase 2 trial update regarding the use of etfi as a combination therapy with the drug Keytruda (pembrolizumab).

The trial, called TACTI-002, “met its primary objective for 1st line non-small cell lung cancer (NSCLC) patients in a PD-L1 all-comer Phase II clinical trial conducted in collaboration with MSD”, the company said.

[The] “combination of efti plus pembrolizumab shows favourable anti-tumour activity…[dosages] were safe and well tolerated, with a safety profile that is consistent with that observed in previously reported studies,” it added.

Speaking on the results, Immutep CEO Marc Voigt said:

We are delighted that patient outcomes are improved with the combination of efti plus pembrolizumab across different patient groups. The data is encouraging for patients, as there is an unmet medical need particularly for those with NSCLC with no or low PD-L1 expression.

Immutep was also on the radar of Pengana High Conviction portfolio manager James McDonald when he spoke to The Motley Fool’s Tony Yoo last month.

McDonald said there was “very substantial upside” to be had in the Immutep share price should the company be able to successfully tap into its US$50 billion addressable market.

In the last 12 months, the Immutep share price has tumbled by more than 43% and is also down around 24% this year to date.

The post What’s driving the Immutep share price in June? appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now

See The 5 Stocks
*Returns as of January 12th 2022

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/THuwm4b

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s